Herald Therapeutics Presents at the ATS Respiratory Innovation Summit
Co-founder and Chief Scientific Officer Dr. David Ingbar presents Herald’s evolution into a platform company advancing multiple indications across two delivery forms at the Breakthroughs in Critical Care Showcase during this year's ATS Respiratory Innovation Summit. Herald Tx is preparing to initiate first pivotal trial in ARDS.
Minneapolis, MN – Herald Therapeutics, Inc., a clinical-stage biopharmaceutical company developing ThyrOxy™, a proprietary lung-delivered, thyroid hormone-based therapeutic platform for life-threatening lung and cardiac diseases, today announced that David H. Ingbar, MD, the company’s co-founder and Chief Scientific Officer, was selected to present in the Breakthroughs in Critical Care Showcase at the American Thoracic Society’s 2026 Respiratory Innovation Summit (RIS), held May 15–16 in Orlando, Florida, as the pre-conference event to the ATS 2026 International Conference. The Summit unites investors, business development leaders, clinicians, and innovators from across the global respiratory ecosystem.
In his presentation, Dr. Ingbar traced Herald’s transformation from a single-asset, single-indication program into a true platform company. ThyrOxy, originally developed as an instilled therapy for intubated patients with acute respiratory distress syndrome (ARDS), is now advancing across three clinical indications using two complementary delivery modalities. Instilled ThyrOxy is the lead candidate for ARDS, where Herald has completed a Phase 1/2a clinical trial. A nebulized formulation of ThyrOxy is advancing through IND-enabling work for acute heart failure (AHF), and the ThyrOxy platform—together with a next-generation prodrug class—is in preclinical development for infant respiratory distress syndrome (IRDS).
“Herald is no longer a one-indication, one-formulation company,” said Dr. Ingbar. “We are a platform addressing several of the most lethal conditions in critical care—ARDS, acute heart failure, and infant RDS—through both direct instillation and nebulization, using an FDA-approved active ingredient. That evolution is what distinguishes Herald today.”
In ARDS, Herald has completed its Phase 1/2a clinical trial of instilled ThyrOxy—showing clinically and statistically significant improvement in oxygenation, reduced ventilator support, and shorter ICU and hospital stays with no drug- or treatment-related adverse events—and is now preparing to initiate its first pivotal trial. The company’s nebulized ThyrOxy program in acute heart failure is moving toward the clinic with support from a grant from the Dr. Ralph and Marian Falk Medical Research Trust, and preclinical work for infant RDS is advancing using both ThyrOxy and a next-generation T3 prodrug class.
“Dr. Ingbar’s presentation captured what has changed about Herald over the past year,” said Wade A. Smith, Chief Executive Officer. “We have evolved into a platform company with three programs across two delivery forms, a de-risked regulatory path, a deep IP estate, and the foundational clinical data to support pivotal development in ARDS. We expect to announce a private capital raise in the near term to fund the pivotal ARDS trial and continue advancing our acute heart failure and infant RDS programs in parallel.”
The Respiratory Innovation Summit is hosted annually by the American Thoracic Society as the pre-conference event to the ATS International Conference and is widely regarded as one of the most important forums in the respiratory industry for emerging and mid-stage companies to engage directly with strategic pharma, venture capital, and clinical leaders. The 2026 Summit drew more than 400 participants from across the global respiratory ecosystem.
About Herald Therapeutics
Herald Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Minneapolis, Minnesota, developing ThyrOxy, a thyroid hormone–based therapeutic platform targeting life-threatening lung and cardiac diseases. The company’s lead programs are in Acute Respiratory Distress Syndrome (ARDS), Infant Respiratory Distress Syndrome (IRDS), and Acute Heart Failure. For more information, please visit heraldtx.com.
Forward-Looking Statements
This press release contains forward-looking statements concerning Herald Therapeutics’ product candidates, including ThyrOxy™, its clinical development plans, regulatory strategy, intellectual property position, and commercial potential. Such statements are based on current expectations and assumptions and are subject to known and unknown risks and uncertainties, including those related to clinical trial results, regulatory review, manufacturing, intellectual property, financing, and competitive developments. Actual results may differ materially from those expressed or implied. Herald Therapeutics undertakes no obligation to update any forward-looking statements except as required by law.
Investor & Media Contact
Wade Smith, CEO
Herald Therapeutics, Inc.
wsmith@heraldtx.com | 412-216-9988